{"entity":{"id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","aka":[],"tldr":"A phase 1/2 trial of VERT-002 in advanced solid tumours, run by Pierre Fabre Medicament, now recruiting.","summary":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations is a phase 1/2 interventional study registered as NCT06669117 by Pierre Fabre Medicament, with 140 participants planned, started 2024-10-22 and due to reach its primary completion in 2030-10-21. Interventions recorded: VERT-002.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06669117","url":"https://clinicaltrials.gov/study/NCT06669117"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["met"],"drugs":[],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06669117","phase":"1/2","setting":"A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations","sponsor":"Pierre Fabre Medicament","started":"2024-10-22","startedType":"actual","enrolled":140,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06669117/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}]}}